Eagle Pharmaceuticals Inc. (EGRX): Douglas Braunstein of Hudson Executive Capital Appointed Chairman

Page 3 of 7 – SEC Filing

CUSIP No.  269796108	SCHEDULE 13D	Page 3 of 6 Pages

1	NAMES OF REPORTING PERSON               Douglas L. Braunstein
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)  ☐  (b)  ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS              AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION            United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER           0
	8	SHARED VOTING POWER           950,600
	9	SOLE DISPOSITIVE POWER           0
	10	SHARED DISPOSITIVE POWER    950,600

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON        950,600

12

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

☐

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
	6.1%(2)
14	TYPE OF REPORTING PERSON
	IN

_______________________________

⁽²⁾ Calculated based on 15,636,387 shares of common stock, par value $0.001 per share, of Eagle Pharmaceuticals, Inc., outstanding as of May 3, 2016, as reported in Eagle Pharmaceuticals, Inc.’s quarterly report on Form 10-Q for the quarter ended March 31, 2016.